Pharma giant CureVac is suing Pfizer's vaccine partner BioNTech over the development of the COVID-19 vaccine.. CureVac has filed a lawsuit against their competitor, claiming patent violations in ...

German biopharmaceutical company CureVac sued BioNTech on Tuesday, seeking "fair compensation" for alleged infringement of intellectual property rights related to the mRNA technology that was used ...

Messenger RNA vaccine biotech CureVac is suing BioNTech, alleging that its rival’s Covid-19 vaccine infringes on intellectual property built on more than two decades of research.

CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

BERLIN, Jan 11 (Reuters) - BioNTech 22UAy.DE has filed a motion to have a German patent held by competitor CureVac 5CV.DE declared invalid in response to a patent lawsuit filed by CureVac last ...

BioNTech has responded by challenging the validity of CureVac’s patents and of its so-called German utility models, which are easier to obtain than patents but confer a shorter exclusivity ...

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% ...

The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month. By Carl Zimmer In early 2020, dozens of scientific teams ...

Like CureVac, BioNTech has made cancer research a top priority. It’s invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody.